In early AD while in a pre-clinical state, it changed more rapidly than the compared CSF for tau (t-Tau or p-Tau-181), demonstrating this ratio as a non-invasive plasma-based bio-marker for early diagnosis and monitoring of AD progression [24]. The gene discussed is MAPT; the disease is Alzheimer disease.